- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
R.Ph.s say AMP rule will drive them out of Medicaid
In a poll of its members, NCPA reported that 86% of community pharmacies stated that the proposed rule governing Medicaid reimbursement for generic drugs would drive them out of the program. The Medicaid program currently bases its federal upper limit (FUL) calculations on average wholesale price (AWP), but under the Deficit Reduction Act of 2005, the agency was directed to change the rate to 250% of the average manufacturers price (AMP). NCPA officials worry that the new ruling may force many community pharmacies out of business and restrict access to medications in many rural and poor urban communities. Citing a GAO report that found that under the rule Medicaid would pay retail pharmacists on average 36% less than their acquisition costs, NCPA executive VP/CEO Bruce Roberts commented: "What we're faced with is not a natural disaster but a public policy disaster."
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
